The GLP-1 surge: What the real-world data reveals
Ozempic and Semaglutide drive a 587% spike in GLP-1 prescriptions Prescriptions for GLP-1 receptor...
Prostate cancer is the most common cancer among men, aside from skin cancer, and is known for being highly diverse in the way that it presents. It often develops as multiple heterogeneous tumors within the prostate, each with its own unique...
Ozempic and Semaglutide drive a 587% spike in GLP-1 prescriptions Prescriptions for GLP-1 receptor...
Prostate cancer is the most common cancer among men, aside from skin cancer, and is known for being...
FDA's AI guidance is reshaping real-world data standards Artificial Intelligence (AI) is rapidly...
Thank you to everyone who joined us at ISPOR 2025 in Montreal. Whether you stopped by our booth,...
Traditional data aggregators are not enough The pharmaceutical industry is hitting a wall. Data...
This is part three of a three-part series on the essential qualities of claims data for life...
This is part two of a three-part series (read part 1, part 3) on the essential qualities of claims...
This is part one of a three-part series (read part 2, part 3) on the essential qualities of claims...
The problem with Zombie Data—And the critical need for Verified Data In life sciences, where...
Highlights Lab results can enhance clinical trials by providing critical data for site selection,...
Ozempic and Semaglutide drive a 587% spike in GLP-1 prescriptions Prescriptions for GLP-1 receptor agonists, including Ozempic, Semaglutide, and Rybelsus, have surged over the last five years as their effectiveness in promoting weight loss gains atte...